Detalhe da pesquisa
1.
Costs to Medicare of Nonrecommended Bone-Modifying Agent Use for Castration-Sensitive Prostate Cancer.
JCO Oncol Pract
; 20(3): 393-400, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38190588
2.
Implementation Strategies to Promote Short-Course Radiation for Bone Metastases.
JAMA Netw Open
; 7(5): e2411717, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38787561
3.
Persistence of Telemedicine Usage for Breast and Prostate Cancer after the Peak of the COVID-19 Pandemic.
Cancers (Basel)
; 15(20)2023 Oct 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37894328